Related references
Note: Only part of the references are listed.Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients
Quan Yuan et al.
GUT (2013)
Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B
Yi-Hsiang Huang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
New insight in the pathobiology of hepatitis B virus infection
Maura Dandri et al.
GUT (2012)
Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean
Nao Nishida et al.
PLOS ONE (2012)
Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis
Yu Xuan Koo et al.
ANNALS OF HEMATOLOGY (2011)
Does rituximab increase the incidence of infectious complications? A narrative review
Theodoros Kelesidis et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2011)
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy
Jorge Mendez-Navarro et al.
LIVER INTERNATIONAL (2011)
Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study
Dongmei Ji et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Relationship between HLA-DP supertype and survival in childhood acute lymphoblastic leukaemia: evidence for selective loss of immunological control of residual disease?
G. Malcolm Taylor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
Winnie Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2009)
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial
Chiun Hsu et al.
HEPATOLOGY (2008)
Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab
Michiko Yamagata et al.
LEUKEMIA & LYMPHOMA (2007)
Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma
G. Perceau et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Kinetics of hepatitis B virus reactivation after chemotherapy: More questions than answers
Chun-Jen Liu et al.
GASTROENTEROLOGY (2006)
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
Chee-Kin Hui et al.
GASTROENTEROLOGY (2006)
Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT
Chun-Jen Liu et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
W Yeo et al.
HEPATOLOGY (2006)
Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis
SH Yeh et al.
JOURNAL OF HEPATOLOGY (2004)
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
GKK Lau et al.
GASTROENTEROLOGY (2003)
Share Paper
